oxybutynin has been researched along with Allodynia in 6 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Excerpt | Relevance | Reference |
---|---|---|
"This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia." | 9.15 | Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. ( Lam, VY; Schulteis, G; Wallace, M, 2011) |
"3°C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia." | 9.15 | Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. ( Andresen, T; Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Upton, RN, 2011) |
"A prospective, open-label, observational study in patients with postherpetic neuralgia, posttraumatic or postsurgical nerve injury, HIV-associated distal sensory polyneuropathy, or other peripheral neuropathic pain, and average daily pain score ≥4, who received ≤6 capsaicin 8% patch treatments over 52 weeks according to clinical need (retreatment at 9 to 12 wk intervals)." | 5.24 | Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study. ( Attal, N; Ernault, E; Gálvez, R; Maihöfner, C; Moyle, G; Navez, ML; Nurmikko, TJ; Stoker, M, 2017) |
"Topical lidocaine (5%) leads to sufficient pain relief in only 29%-80% of treated patients, presumably by small-fiber block." | 5.16 | Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers. ( Krumova, EK; Maier, C; Westermann, A; Zeller, M, 2012) |
"This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia." | 5.15 | Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. ( Lam, VY; Schulteis, G; Wallace, M, 2011) |
"3°C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia." | 5.15 | Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. ( Andresen, T; Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Upton, RN, 2011) |
" The capsaicin 8% patch is a Food and Drug Administration-approved treatment of neuropathic pain in postherpetic neuralgia and has demonstrated significant efficacy in human immunodeficiency virus-autonomic neuropathy." | 3.81 | Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury: Two Case Reports. ( Trbovich, M; Yang, H, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gálvez, R | 1 |
Navez, ML | 1 |
Moyle, G | 1 |
Maihöfner, C | 1 |
Stoker, M | 1 |
Ernault, E | 1 |
Nurmikko, TJ | 1 |
Attal, N | 1 |
Madsen, CS | 1 |
Johnsen, B | 1 |
Fuglsang-Frederiksen, A | 1 |
Jensen, TS | 1 |
Finnerup, NB | 1 |
Trbovich, M | 1 |
Yang, H | 1 |
Lam, VY | 1 |
Wallace, M | 1 |
Schulteis, G | 1 |
Andresen, T | 1 |
Upton, RN | 1 |
Foster, DJ | 1 |
Christrup, LL | 1 |
Arendt-Nielsen, L | 1 |
Drewes, AM | 1 |
Krumova, EK | 1 |
Zeller, M | 1 |
Westermann, A | 1 |
Maier, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 trials available for oxybutynin and Allodynia
Article | Year |
---|---|
Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study.
Topics: Aged; Analgesics, Non-Narcotic; Capsaicin; Female; Humans; Hyperalgesia; Male; Middle Aged; Neuralgi | 2017 |
Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial.
Topics: Anesthetics, Local; Capsaicin; Double-Blind Method; Humans; Hyperalgesia; Injections, Intradermal; L | 2011 |
Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Capsaicin; Cold Temperature; Cross-Over Studies; Dose-Resp | 2011 |
Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers.
Topics: Adult; Aged; Anesthetics, Local; Double-Blind Method; Female; Humans; Hyperalgesia; Lidocaine; Male; | 2012 |
2 other studies available for oxybutynin and Allodynia
Article | Year |
---|---|
Differential effects of a 5% lidocaine medicated patch in peripheral nerve injury.
Topics: Adult; Anesthetics, Local; Evoked Potentials; Female; Humans; Hyperalgesia; Lidocaine; Male; Middle | 2013 |
Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury: Two Case Reports.
Topics: Adult; Aged; Capsaicin; Humans; Hyperalgesia; Male; Neuralgia; Pain Measurement; Sensory System Agen | 2015 |